Platform
A cancer biomarker platform that reads tumour chemistry
Digistain is a pan-tumour, vendor-neutral cancer biomarker platform. It measures the tumour’s biochemistry directly from routine tissue, and each product applies that measurement to a specific clinical question.
A Digistain mid-infrared chemical image of a tissue section.
What it measures
Chemistry that reflects chromosomal instability
Mid-infrared spectroscopy measures chemical moieties such as phosphate and amide in unstained tissue sections. From these, the Digistain Index gives the nuclear-to-cytoplasmic chemical ratio, which reflects aneuploidy: the chromosomal instability associated with aggressive tumours.
Source: Coombes et al., Breast Cancer Research and Treatment, 2024. Wording subject to scientific review.
How it is delivered
Run locally, or through our laboratory
Hospitals and laboratories can run the test and issue results themselves, or use Digistain’s laboratory service.
The published method uses an inexpensive spectrometer and no costly reagents (Coombes et al., 2024).
Products and research
Breast first, then further cancers
Digistain Breast
Prognostic recurrence-risk score for HR-positive, HER2-negative, stage I–II breast cancer with 0–3 positive lymph nodes.
Kidney, lung and prostate cancer
Research is under way. These applications are investigational, not available for clinical use.